Subscribe to Search results

At a meeting of the CSM(B), Dr Smith reported that preliminary evidence suggested that heat treatment would reduce the potential of transmitting AIDs via blood products.

Published on:

In a letter to R Nicholson (Immuno), M E Duncan (DHSS) confirmed that the Licensing Authority encouraged pharmaceutical companies to use a dry heat treatment process.

Published on:

An internal Cutter memo stated that AIDs had caused a virtual panic in the Department of Health, and that the Department had blocked every application for registration of heat-treated Factor 8 for a year.

Published on:

The DHSS began to collect data on the ability of heat-treated blood products to inactivate HIV.

Published on:

Immuno made an application for Kryobulin TIM 2.

Published on:

Dr Frances Rotblat (DHSS) was recorded as having told Cutter that it was extremely rare for the yellow card system for reporting adverse reactions to be used for hepatitis in blood products.

Published on:

Between 1970 and 1995 the Yellow Card reporting scheme for adverse drug reactions was limited to medical practitioners.

Published on:

In an affidavit, Professor Adolf Asscher stated that there was an established process of investigating reports of serious adverse reactions.

Published on:

The British Pharmacopoeia did not contain references the risk of AIDs associated with the use of commercial factor concentrates between 1983 and 1985.

Published on:

The CSM declined to grant a licence for Serum Cholinesterase.

Published on:

In a memo to Mr Wrigglesworth, Dr Fowler recorded the results of the FDA meeting held on 19 July 1983. The possibility of banning all products made before the FDA's March 1983 Regulations was rejected.

Published on:

A. W. Burrell (Managing Director, Travenol) wrote a letter to Dr Walford advising her that "well before" the FDA's 24 March recommendation, Hyland had taken steps to introduce screening procedures designed to eliminate high-risk donors.

Published on:

The Haemophilia Society planned a meeting with the junior Minister, Geoffrey Finsberg, to seek his assurance that there would be no immediate ban on the importation of US blood products.

Published on:

In a memo to Dr Walford, Dr Oliver (DHSS) expressed the opinion that the assurance from pharmaceutical companies that future sales after June 1983 would comply with FDA guidelines was vague.

Published on:

A product licence was granted to Cutter for Factor 8 heat-treated via pasteurisation.

Published on:

Between 1970 and 1995 there were 144 Yellow Card reports relating to blood products on the Register of Adverse Reactions maintained by CSM.

Published on:

Dr Thomas was invited to speak at a meeting of the Scottish National Blood Transfusion Association.He is reported to have said, "Both the commercial products now licensed had come from factories inspected by DHSS; samples and protocols had been sent to the National Institute of Biological Standards and Quality Control...No British blood product underwent similar inspection."

Published on:

Hospital Week reported a special message delivered by President Richard Nixon on Health Care in which he called for a a 'safe, fast and efficient blood collection and distribution system' arising from a general understanding by the authorities that the current system was inadequate; hospitals were often forced to buy blood which came from high risk donors such as drug addicts and derelicts.

Published on:

Dr Sheila Waiter noted that, "while it is generally accepted that the benefits of having Hemofil available for the treatment of bleeding episodes far out-weigh the risk of acquiring hepatitis B nevertheless the statement that 'every lot of this particular product is probably contaminated with hepatitis B virus' will come as a surprise to many clinicians using the product".

Published on:

Dr Harvey J Alter, Professor Paul Vincent Holland, Robert H Purcell and John L Gerin concluded that that RIA testing, which by then was available, was clearly more sensitive than CEP for revealing Hepatitis B surface antigen.

Published on: